For over three decades, HDACs have been targeted for various cancer treatments which have resulted in the approval of five HDAC inhibitors with several others in clinical trials for the treatment of several types of cancer [26,27,28,29,30,31,32,33,34,35,36,37,38]. This evidence concerns the gene HDAC9 and cancer.